Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.

Dalla Costa, Gloria; Leocani, Letizia; Montalban, Xavier; Guerrero, Ana Isabel; Sørensen, Per Soelberg; Magyari, Melinda; Dobson, Richard J B; Cummins, Nicholas; Narayan, Vaibhav A; Hotopf, Matthew; Comi, Giancarlo

Dalla Costa, Gloria; Leocani, Letizia; Montalban, Xavier; Guerrero, Ana Isabel; Sørensen, Per Soelberg; Magyari, Melinda; Dobson, Richard J B; Cummins, Nicholas; Narayan, Vaibhav A; Hotopf, Matthew; Comi, Giancarlo.

Dalla Costa G; Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, via Olgettina 60, 20132, Milan, Italy.
Leocani L; Neurorehabilitation Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
Montalban X; Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, via Olgettina 60, 20132, Milan, Italy.
Guerrero AI; Neurorehabilitation Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
Sørensen PS; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Magyari M; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Dobson RJB; Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Cummins N; Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Narayan VA; The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Hotopf M; Institute of Health Informatics, University College London, London, UK.
Comi G; Embedded Intelligence for Health Care & Wellbeing, University of Augsburg, Augsburg, Germany.

Neurol Sci ; 41(7): 1647-1650, 2020 Jul.

Artículo en Inglés | MEDLINE | ID: covidwho-621528

ABSTRACT

ABSTRACT

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

Asunto(s)

Betacoronavirus; Infecciones por Coronavirus/epidemiología; Esclerosis Múltiple/epidemiología; Esclerosis Múltiple/virología; Neumonía Viral/epidemiología; Adulto; Alemtuzumab/uso terapéutico; COVID-19; Infecciones por Coronavirus/tratamiento farmacológico; Europa (Continente); Femenino; Humanos; Estudios Longitudinales; Masculino; Persona de Mediana Edad; Esclerosis Múltiple/complicaciones; Pandemias; Neumonía Viral/tratamiento farmacológico; Prevalencia; SARS-CoV-2

Palabras clave

COVID-19; Multiple Sclerosis; Remote monitoring technologies

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Betacoronavirus / Esclerosis Múltiple Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Femenino / Humanos / Masculino / Middle aged País/Región como asunto: Europa Idioma: Inglés Revista: Neurol Sci Asunto de la revista: Neurología Año: 2020 Tipo del documento: Artículo País de afiliación: S10072-020-04519-x

Similares

MEDLINE

LILACS

LIS

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google